Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Urcosmid is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, typically found on immune ...

RPESC-RPE-4W is a proprietary retinal pigment epithelium cell therapy for patients with dry age-related macular degeneration.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous ...

Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

The Australian Society of Ophthalmologists (ASO) announces the appointment of Katrina Ronne as its first woman chief ...

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals ...

The findings were from 6 patients in the first low-dose cohort of the ongoing first-in-human trial (NCT04627428).

At the EnVision Summit 2025 in San Juan, Puerto Rico, Poonam Misra, MD, and Alcina Lidder, MD, gave advice on managing ...

To tackle systemic barriers to eye care, the organization is co-hosting an event titled “No Woman Left Behind – Advancing Eye ...

The procedure offers a renewed approach to suprachoroidal drainage, with potential for both combined and standalone glaucoma ...